Idorsia Ltd Secures CHF 250 million Senior Secured Term Loan, Strengthening Liquidity
Idorsia Ltd (SIX: IDIA), a Swiss biopharmaceutical company focused on therapeutics for insomnia, Fabry disease, cerebral vasospasm, resistant hypertension, and lupus, announced on 9 June 2026 that it has entered into a senior secured term loan agreement with investment funds managed by Pharmakon Advisors, LP.
Key Terms of the Credit Facility
| Item | Detail |
|---|---|
| Maximum Principal | CHF 250 million |
| First Tranche | CHF 150 million to be provided at closing |
| Maturity | Five years |
| Interest Rate | Fixed 7 % |
| Purpose | Initially to refinance the existing New Money Facility, which is set to mature in May 2027, and to eliminate near‑term debt maturities |
The new loan replaces the New Money Facility, which has drawn CHF 105 million to date. By doing so, Idorsia removes impending debt obligations that were due in 2027, thereby improving its balance‑sheet profile and extending liquidity coverage until 2028.
Market Reaction
Shares of Idorsia rose following the announcement. The company’s stock closed at CHF 4.22 on 7 June 2026, a decline of 46 % from the CHF 7.82 level three years earlier when the shares first traded on the SIX Swiss Exchange. The 52‑week range for the stock is CHF 1.80 to CHF 4.87, underscoring the volatility investors have experienced.
Financial Context
- Market Capitalisation: CHF 1.096 billion (as of 7 June 2026)
- Price‑Earnings Ratio: –4.47 (negative earnings)
- Currency: CHF
- Sector: Health Care, Biotechnology
The infusion of capital will support Idorsia’s ongoing research and development activities and potentially fund targeted initiatives that accelerate growth and long‑term value creation, as outlined in the company’s public statement.
Summary
Idorsia’s recent refinancing of debt through a CHF 250 million senior secured term loan at a fixed 7 % interest rate strengthens its liquidity position, eliminates near‑term maturities, and provides the company with additional financial flexibility to pursue its therapeutic pipeline and strategic objectives.
